| Item Type | Name |
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
|
Concept
|
Lung Neoplasms
|
|
Concept
|
Lung
|
|
Concept
|
Carcinoma, Lewis Lung
|
|
Concept
|
Acute Lung Injury
|
|
Concept
|
Small Cell Lung Carcinoma
|
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
|
Academic Article
|
Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.
|
|
Academic Article
|
Molecular abnormalities in lung cancer.
|
|
Academic Article
|
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
|
|
Academic Article
|
Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma.
|
|
Academic Article
|
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.
|
|
Academic Article
|
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
|
|
Academic Article
|
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
|
|
Academic Article
|
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
|
|
Academic Article
|
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
|
|
Academic Article
|
Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.
|
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
|
Academic Article
|
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
|
|
Academic Article
|
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
|
|
Academic Article
|
Molecular alterations in lung cancer. Impact on prognosis.
|
|
Academic Article
|
Small cell lung cancer: from molecular biology to novel therapeutics.
|
|
Academic Article
|
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
|
|
Academic Article
|
Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer.
|
|
Academic Article
|
Targeted molecules in small cell lung cancer.
|
|
Academic Article
|
p53 and Bcl-2 in small cell-lung cancer.
|
|
Academic Article
|
Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system.
|
|
Academic Article
|
Phase II study of imatinib in patients with small cell lung cancer.
|
|
Academic Article
|
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
|
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
|
Academic Article
|
Novel therapies in lung cancer.
|
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
|
Academic Article
|
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
|
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
|
Academic Article
|
c-Met inhibition.
|
|
Academic Article
|
A review of topoisomerase inhibition in lung cancer.
|
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
|
Academic Article
|
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors.
|
|
Academic Article
|
Lung carcinoma in African Americans.
|
|
Academic Article
|
Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue.
|
|
Academic Article
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
|
Academic Article
|
MET as a target for treatment of chest tumors.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
|
Academic Article
|
Biology and novel therapeutics for neuroendocrine tumors of the lung.
|
|
Academic Article
|
Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1.
|
|
Academic Article
|
Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.
|
|
Academic Article
|
Receptor tyrosine kinases and inhibitors in lung cancer.
|
|
Academic Article
|
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.
|
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
|
Academic Article
|
Stamp out lung cancer.
|
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
|
Academic Article
|
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
|
|
Academic Article
|
MET receptor tyrosine kinase.
|
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
|
Academic Article
|
The role of chemokine receptor CXCR4 in lung cancer.
|
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
|
Academic Article
|
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
|
|
Academic Article
|
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
|
|
Academic Article
|
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
|
|
Academic Article
|
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.
|
|
Academic Article
|
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
|
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
|
Academic Article
|
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer.
|
|
Academic Article
|
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
|
|
Academic Article
|
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways.
|
|
Academic Article
|
A novel classification of lung cancer into molecular subtypes.
|
|
Academic Article
|
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
|
|
Academic Article
|
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
|
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
|
Academic Article
|
Mind-mapping for lung cancer: towards a personalized therapeutics approach.
|
|
Academic Article
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
|
Academic Article
|
Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.
|
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
|
Academic Article
|
The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer.
|
|
Academic Article
|
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
|
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.
|
|
Academic Article
|
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
|
Academic Article
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
|
Academic Article
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
|
Academic Article
|
MET molecular mechanisms and therapies in lung cancer.
|
|
Academic Article
|
Personalized treatment of lung cancer.
|
|
Academic Article
|
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.
|
|
Academic Article
|
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
|
|
Academic Article
|
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.
|
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
|
Academic Article
|
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance.
|
|
Academic Article
|
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups.
|
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
|
Academic Article
|
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma.
|
|
Academic Article
|
Case 1: small bowel obstruction due to metastatic lung cancer.
|
|
Academic Article
|
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
|
|
Academic Article
|
Detection and analysis of lung cancer cells from body fluids using a rare event imaging system.
|
|
Academic Article
|
Molecular and cellular biology of small cell lung cancer.
|
|
Academic Article
|
Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung.
|
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
|
Academic Article
|
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
|
|
Academic Article
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
|
Academic Article
|
Key signaling pathways and targets in lung cancer therapy.
|
|
Academic Article
|
Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
|
|
Academic Article
|
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
|
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
|
Academic Article
|
MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.
|
|
Academic Article
|
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
|
|
Academic Article
|
Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.
|
|
Academic Article
|
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
|
Academic Article
|
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
|
|
Academic Article
|
Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
Evidence-based role of bevacizumab in non-small cell lung cancer.
|
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
|
|
Academic Article
|
Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases.
|
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
|
Academic Article
|
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.
|
|
Academic Article
|
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
|
|
Academic Article
|
Increased µ-opioid receptor expression in metastatic lung cancer.
|
|
Academic Article
|
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
|
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
|
Academic Article
|
Molecular biomarkers for future screening of lung cancer.
|
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
|
Academic Article
|
Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.
|
|
Academic Article
|
Mitochondrial dynamics: biology and therapy in lung cancer.
|
|
Academic Article
|
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.
|
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
|
Academic Article
|
Molecular pathways and therapeutic targets in lung cancer.
|
|
Academic Article
|
Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.
|
|
Academic Article
|
Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.
|
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
|
Academic Article
|
Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening.
|
|
Academic Article
|
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
|
|
Academic Article
|
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
|
|
Academic Article
|
Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
|
Academic Article
|
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
|
|
Academic Article
|
Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.
|
|
Academic Article
|
c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury.
|
|
Academic Article
|
A new PET/CT volumetric prognostic index for non-small cell lung cancer.
|
|
Academic Article
|
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
|
|
Academic Article
|
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
|
|
Academic Article
|
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
|
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
|
Academic Article
|
Lung cancer-a fractal viewpoint.
|
|
Academic Article
|
ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
|
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
|
Academic Article
|
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.
|
|
Academic Article
|
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
|
|
Academic Article
|
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial.
|
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
|
Academic Article
|
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
|
|
Academic Article
|
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
|
|
Academic Article
|
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
|
|
Academic Article
|
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
|
|
Academic Article
|
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
|
|
Academic Article
|
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.
|
|
Academic Article
|
DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER.
|
|
Academic Article
|
KRAS in Non-Small-Cell Lung Cancer-Reply.
|
|
Academic Article
|
Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.
|
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
|
Academic Article
|
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
|
|
Academic Article
|
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
|
|
Academic Article
|
A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer.
|
|
Academic Article
|
CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC).
|
|
Academic Article
|
Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naïve advanced non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
|
|
Academic Article
|
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Academic Article
|
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
|
|
Academic Article
|
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
|
|
Academic Article
|
Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
|
|
Academic Article
|
EphB4: A promising target for upper aerodigestive malignancies.
|
|
Academic Article
|
Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
|
|
Academic Article
|
Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.
|
|
Academic Article
|
Managing Patients With Relapsed Small-Cell Lung Cancer.
|
|
Academic Article
|
Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.
|
|
Academic Article
|
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
|
|
Academic Article
|
Heuristic value-based framework for lung cancer decision-making.
|
|
Academic Article
|
State-of-the-art considerations in small cell lung cancer brain metastases.
|
|
Academic Article
|
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.
|
|
Academic Article
|
The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.
|
|
Academic Article
|
RLIP inhibition suppresses breast-to-lung metastasis.
|
|
Academic Article
|
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
|
|
Academic Article
|
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Early mortality of stage IV non-small cell lung cancer in the United States.
|
|
Academic Article
|
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
|
|
Academic Article
|
Targeted Therapies in Non-small-Cell Lung Cancer.
|
|
Academic Article
|
Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.
|
|
Academic Article
|
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.
|
|
Academic Article
|
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.
|
|
Academic Article
|
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
|
|
Academic Article
|
Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells.
|
|
Academic Article
|
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
|
|
Academic Article
|
Precision medicine and actionable alterations in lung cancer: A single institution experience.
|
|
Academic Article
|
Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
|
|
Academic Article
|
Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines.
|
|
Academic Article
|
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
|
|
Academic Article
|
Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach.
|
|
Academic Article
|
The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy.
|
|
Academic Article
|
Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites.
|
|
Academic Article
|
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
|
|
Academic Article
|
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
|
|
Academic Article
|
Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.
|
|
Academic Article
|
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?
|
|
Academic Article
|
Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics.
|
|
Academic Article
|
Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.
|
|
Academic Article
|
A Non-genetic Mechanism Involving the Integrin ß4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer.
|
|
Academic Article
|
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
|
|
Academic Article
|
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease.
|
|
Academic Article
|
Erratum: A Non-genetic Mechanism Involving the Integrin ß4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer.
|
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
|
Academic Article
|
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
|
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
|
Academic Article
|
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure.
|
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
|
Academic Article
|
Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey.
|
|
Academic Article
|
Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
|
|
Academic Article
|
Disparate outcomes in nonsmall cell lung cancer by immigration status.
|
|
Academic Article
|
RNA-based therapies: A cog in the wheel of lung cancer defense.
|
|
Academic Article
|
Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer.
|
|
Academic Article
|
ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation.
|
|
Academic Article
|
Germline mutations and age at onset of lung adenocarcinoma.
|
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
|
Academic Article
|
Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.
|
|
Academic Article
|
Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
|
|
Academic Article
|
Biologically Active Volume of Disease (BaVD) Predicts for Survival in Metastatic Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
|
|
Academic Article
|
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
|
|
Academic Article
|
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?
|
|
Academic Article
|
The next targets for small cell lung cancer.
|
|
Academic Article
|
Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy.
|
|
Academic Article
|
Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
|
|
Academic Article
|
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
|
Academic Article
|
Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer.
|
|
Academic Article
|
Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics.
|
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
|
Academic Article
|
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
|
|
Academic Article
|
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk.
|
|
Academic Article
|
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.
|
|
Academic Article
|
An Updated Review on Radiation Treatment Management in Thymus Cancers.
|
|
Academic Article
|
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
|
|
Academic Article
|
Integration of artificial intelligence in lung cancer: Rise of the machine.
|
|
Academic Article
|
Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma.
|
|
Academic Article
|
Overcoming Barriers to Tobacco Cessation and Lung Cancer Screening among Racial and Ethnic Minority Groups and Underserved Patients in Academic Centers and Community Network Sites: The City of Hope Experience.
|
|
Academic Article
|
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
|
|
Academic Article
|
Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer.
|
|
Academic Article
|
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.
|
|
Grant
|
Role of Paxillin in Lung Cancer
|
|
Grant
|
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
|
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
|
Academic Article
|
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
|
|
Academic Article
|
LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancer.
|
|
Academic Article
|
Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.
|
|
Academic Article
|
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
|
|
Academic Article
|
Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors.
|
|
Academic Article
|
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies.
|
|
Academic Article
|
Phase II Trial of Lung Chemoembolization.
|
|
Academic Article
|
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
|
|
Academic Article
|
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
|
|
Academic Article
|
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.
|